Article · 5 Oct 2026
Conference abstract
TDI - DDI risk assessment from In Vitro to In Vivo - Application of PBPK modeling and simulation tool
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T ime-dependent inhibition (TDI) is an important consideration in the drug development process. To date, methods to accurately predict the magnitude of a clinical drug-drug interaction (DDI) from pre-clinical TDI data have been lacking. Until relatively recently, the application of PBPK modeling in support of drug discovery and early development was somewhat limited due to the resource-intensive ADME data required to fully populate PBPK models and the mathematical complexity of the model itself. However, advances in in silico/in vitro -based prediction tools, in particular those for absorption, distribution and hepatic clearance, have enabled the use of PBPK modeling at an earlier stage of drug discovery. In addition, the emergence of software tools, such as GastroPlus? and the Simcyp? simulator, allow for a broader use of PBPK models. Although more complex prediction algorithms have been developed, the accuracy has still improved little. Historically, human liver microsomes have been used to generate inhibition kinetic data used for in vivo DDI predictions. Recently, it has been suggested that human hepatocytes TDI kinetic data may provide a better prediction for assessing clinical DDI related to TDI. Our work evaluates and optimizes a human hepatocyte assay for the assessment of CYP3A4 TDI using pooled cryopreserved human hepatocytes. Using two different optimized methods, the time-dependent inhibition kinetic parameters for four known CYP3A4 TDI, diltiazem, erythromycin, verapamil, and troleandomycin, were determined. When drug interactions were simulated with Simcyp PBPK model, the predictions using the kinetic parameters from human hepatocyte resulted in a much better simulated change in pharmacokinetics when compared with observed clinical data.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yuan Chen”